Addenbrookes Major Trauma Unit, Department of Trauma And Orthopaedics, Cambridge University Hospitals, Cambridge, UK.
Watford General Hospital, London, UK.
Tissue Eng Regen Med. 2023 Oct;20(6):793-809. doi: 10.1007/s13770-023-00557-6. Epub 2023 Aug 31.
Recent studies of exosomes derived from mesenchymal stem cells (MSCs) have indicated high potential clinical applications in many diseases. However, the limited source of MSCs impedes their clinical research and application. Most recently, induced pluripotent stem cells (iPSCs) have become a promising source of MSCs. Exosome therapy based on iPSC-derived MSCs (iMSCs) is a novel technique with much of its therapeutic potential untapped. Compared to MSCs, iMSCs have proved superior in cell proliferation, immunomodulation, generation of exosomes capable of controlling the microenvironment, and bioactive paracrine factor secretion, while also theoretically eliminating the dependence on immunosuppression drugs. The therapeutic effects of iMSC-derived exosomes are explored in many diseases and are best studied in wound healing, cardiovascular disease, and musculoskeletal pathology. It is pertinent clinicians have a strong understanding of stem cell therapy and the latest advances that will eventually translate into clinical practice. In this review, we discuss the various applications of exosomes derived from iMSCs in clinical medicine.
最近对间充质干细胞(MSCs)衍生的外泌体的研究表明,它们在许多疾病中有很高的临床应用潜力。然而,MSCs 的有限来源阻碍了它们的临床研究和应用。最近,诱导多能干细胞(iPSCs)已成为 MSCs 的一个有前途的来源。基于 iPSC 衍生的间充质干细胞(iMSCs)的外泌体治疗是一种新技术,其大部分治疗潜力尚未开发。与 MSCs 相比,iMSCs 在细胞增殖、免疫调节、产生能够控制微环境的外泌体以及生物活性旁分泌因子的分泌方面表现出优越性,同时理论上也消除了对免疫抑制药物的依赖。iMSC 衍生的外泌体在许多疾病中的治疗效果得到了探索,在创伤愈合、心血管疾病和肌肉骨骼病理学方面的研究最为深入。因此,临床医生需要对干细胞治疗有深入的了解,并掌握最终将转化为临床实践的最新进展。在这篇综述中,我们讨论了 iMSC 衍生的外泌体在临床医学中的各种应用。